Satellos completes enrollment in BASECAMP Phase 2 forazapadin trial; topline due Q1 2027

Satellos completed enrollment in BASECAMP, a Phase 2 forazapadin trial in Duchenne muscular dystrophy. No results have been presented; topline data are now expected in Q1 2027 after timing was pushed back to compile a more complete dataset for potential FDA discussions on an accelerated development path.